Expression and potential role of CCL4 in CD8+T cells in NSCLC.
Antigens, Neoplasm
B7-H1 Antigen
/ metabolism
CD8-Positive T-Lymphocytes
Carcinoma, Non-Small-Cell Lung
/ pathology
Chemokine CCL4
/ genetics
ErbB Receptors
/ genetics
Humans
Ligands
Lung Neoplasms
/ pathology
Lymphocytes, Tumor-Infiltrating
/ metabolism
Mutation
Programmed Cell Death 1 Receptor
/ metabolism
Protein-Tyrosine Kinases
/ genetics
Proto-Oncogene Proteins
/ genetics
Receptor Protein-Tyrosine Kinases
/ genetics
Tumor Microenvironment
CCL4
CD8+T cells
Infiltration of immune cells
Methylation
NSCLC
Journal
Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico
ISSN: 1699-3055
Titre abrégé: Clin Transl Oncol
Pays: Italy
ID NLM: 101247119
Informations de publication
Date de publication:
Dec 2022
Dec 2022
Historique:
received:
19
05
2022
accepted:
27
07
2022
pubmed:
15
8
2022
medline:
19
10
2022
entrez:
14
8
2022
Statut:
ppublish
Résumé
Under the continuous stimulation of tumor antigen in the tumor microenvironment, CD8+T cells will enter a state of functional defect or failure, which cannot effectively prevent the progression of lung cancer. Therefore, finding potential targets for immunotherapy in lung cancer has broad prospects. In the early stage of this study, the genes related to immune infiltration in lung cancer were found through the analysis on multiple datasets (GSE116959, GSE139032 and GSE111894). Characteristics of candidate genes were identified from transcriptome, methylation, single cell sequencing and other dimensions, respectively. Moreover, the correlation between candidate genes and immunotherapy-related genes and mutated genes of lung cancer was further identified. Finally, the expression of the candidate genes was detected with an online immunohistochemistry database. According to the above research, it was found that CCL4 (chemokine (C-C motif) ligand 4) was abnormally highly expressed in samples from patients with NSCLC and had certain methylation characteristics. In addition, CCL4 was also closely associated with infiltration of immune cells, such as B cells and CD8+T cells. Interestingly, the aberrant expression of CCL4 affected the survival of CD8+T cells. Single cell sequencing results also showed that CCL4 was highly expressed in CD8+T cells and was involved in biological functions such as generation cycle. Finally, CCL4 expression was positively associated with PD-1 and PD-L1, and also with mutant genes, such as EGFR, ALK and ROS1, associated with the treatment for lung cancer. CCL4 may be a potential target for immunotherapy in patients with NSCLC.
Identifiants
pubmed: 35964269
doi: 10.1007/s12094-022-02913-9
pii: 10.1007/s12094-022-02913-9
doi:
Substances chimiques
Antigens, Neoplasm
0
B7-H1 Antigen
0
CCL4 protein, human
0
Chemokine CCL4
0
Ligands
0
Programmed Cell Death 1 Receptor
0
Proto-Oncogene Proteins
0
ErbB Receptors
EC 2.7.10.1
Protein-Tyrosine Kinases
EC 2.7.10.1
Receptor Protein-Tyrosine Kinases
EC 2.7.10.1
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
2420-2431Informations de copyright
© 2022. The Author(s), under exclusive licence to Federación de Sociedades Españolas de Oncología (FESEO).
Références
Bade BC, Dela Cruz CS. Lung cancer 2020: epidemiology, etiology, and prevention. Clin Chest Med. 2020;41(1):1–24.
doi: 10.1016/j.ccm.2019.10.001
Wu F, Wang L, Zhou C. Lung cancer in China: current and prospect. Curr Opin Oncol. 2021;33(1):40–6.
doi: 10.1097/CCO.0000000000000703
Ruiz-Cordero R, Devine WP. Targeted therapy and checkpoint immunotherapy in lung cancer. Surg Pathol Clin. 2020;13(1):17–33.
doi: 10.1016/j.path.2019.11.002
Paijens ST, Vledder A, de Bruyn M, Nijman HW. Tumor-infiltrating lymphocytes in the immunotherapy era. Cell Mol Immunol. 2021;18(4):842–59.
doi: 10.1038/s41423-020-00565-9
Reina-Campos M, Scharping NE, Goldrath AW. CD8(+) T cell metabolism in infection and cancer. Nat Rev Immunol. 2021;21(11):718–38.
doi: 10.1038/s41577-021-00537-8
Jiang X, Xu J, Liu M, Xing H, Wang Z, Huang L, Mellor AL, Wang W, Wu S. Adoptive CD8(+) T cell therapy against cancer: challenges and opportunities. Cancer Lett. 2019;462:23–32.
doi: 10.1016/j.canlet.2019.07.017
Qin S, Xu L, Yi M, Yu S, Wu K, Luo S. Novel immune checkpoint targets: moving beyond PD-1 and CTLA-4. Mol Cancer. 2019;18(1):155.
doi: 10.1186/s12943-019-1091-2
Rotte A. Combination of CTLA-4 and PD-1 blockers for treatment of cancer. J Exp Clin Cancer Res. 2019;38(1):255.
doi: 10.1186/s13046-019-1259-z
Li X, Li Z, Zhu H, Yu X. Autophagy regulatory genes MET and RIPK2 play a prognostic role in pancreatic ductal adenocarcinoma: a bioinformatic analysis based on GEO and TCGA. Biomed Res Int. 2020;2020:8537381.
pubmed: 33204717
pmcid: 7665929
Broderick SR. Adjuvant and neoadjuvant immunotherapy in non-small cell lung cancer. Thorac Surg Clin. 2020;30(2):215–20.
doi: 10.1016/j.thorsurg.2020.01.001
Saika F, Kiguchi N, Kobayashi Y, Fukazawa Y, Kishioka S. CC-chemokine ligand 4/macrophage inflammatory protein-1beta participates in the induction of neuropathic pain after peripheral nerve injury. Eur J Pain. 2012;16(9):1271–80.
doi: 10.1002/j.1532-2149.2012.00146.x
Chang TT, Lin LY, Chen JW. A novel resolution of diabetes: C–C chemokine motif ligand 4 is a common target in different types of diabetes by protecting pancreatic islet cell and modulating inflammation. Front Immunol. 2021;12: 650626.
doi: 10.3389/fimmu.2021.650626
Schwartzkopff F, Petersen F, Grimm TA, Brandt E. CXC chemokine ligand 4 (CXCL4) down-regulates CC chemokine receptor expression on human monocytes. Innate Immun. 2012;18(1):124–39.
doi: 10.1177/1753425910388833
Shamoun L, Landerholm K, Balboa Ramilo A, Andersson RE, Dimberg J, Wagsater D. Association of gene and protein expression and genetic polymorphism of CC chemokine ligand 4 in colorectal cancer. World J Gastroenterol. 2021;27(30):5076–87.
doi: 10.3748/wjg.v27.i30.5076
Mukaida N, Sasaki SI, Baba T. CCL4 signaling in the tumor microenvironment. Adv Exp Med Biol. 2020;1231:23–32.
doi: 10.1007/978-3-030-36667-4_3
Li L, Liu YD, Zhan YT, Zhu YH, Li Y, Xie D, Guan XY. High levels of CCL2 or CCL4 in the tumor microenvironment predict unfavorable survival in lung adenocarcinoma. Thorac Cancer. 2018;9(7):775–84.
doi: 10.1111/1759-7714.12643
Klutstein M, Nejman D, Greenfield R, Cedar H. DNA methylation in cancer and aging. Cancer Res. 2016;76(12):3446–50.
doi: 10.1158/0008-5472.CAN-15-3278
Ding W, Chen G, Shi T. Integrative analysis identifies potential DNA methylation biomarkers for pan-cancer diagnosis and prognosis. Epigenetics. 2019;14(1):67–80.
doi: 10.1080/15592294.2019.1568178
Kel A, Boyarskikh U, Stegmaier P, Leskov LS, Sokolov AV, Yevshin I, Mandrik N, Stelmashenko D, Koschmann J, Kel-Margoulis O, et al. Walking pathways with positive feedback loops reveal DNA methylation biomarkers of colorectal cancer. BMC Bioinformatics. 2019;20(Suppl 4):119.
doi: 10.1186/s12859-019-2687-7
Somoracz A, Kuthi L, Micsik T, Jenei A, Hajdu A, Vrabely B, Raso E, Sapi Z, Bajory Z, Kulka J, et al. Renal cell carcinoma with clear cell papillary features: perspectives of a differential diagnosis. Pathol Oncol Res. 2020;26(3):1767–76.
doi: 10.1007/s12253-019-00757-3
Chen Q, Yin H, Pu N, Zhang J, Zhao G, Lou W, Wu W. Chemokine C–C motif ligand 21 synergized with programmed death-ligand 1 blockade restrains tumor growth. Cancer Sci. 2021;112(11):4457–69.
doi: 10.1111/cas.15110
Gu Y, Li X, Bi Y, Zheng Y, Wang J, Li X, Huang Z, Chen L, Huang Y, Huang Y. CCL14 is a prognostic biomarker and correlates with immune infiltrates in hepatocellular carcinoma. Aging (Albany NY). 2020;12(1):784–807.
doi: 10.18632/aging.102656
Wang Y, Chen H, Zhang T, Yang X, Zhong J, Wang Y, Chi Y, Wu M, An T, Li J, et al. Plasma cytokines interleukin-18 and C-X-C motif chemokine ligand 10 are indicative of the anti-programmed cell death protein-1 treatment response in lung cancer patients. Ann Transl Med. 2021;9(1):33.
doi: 10.21037/atm-20-1513
Chen S, Yang L, Dong H, Guo H. Human telomerase reverse transcriptase recruits the beta-catenin/TCF-4 complex to transactivate chemokine (C–C motif) ligand 2 expression in colorectal cancer. Biomed Pharmacother. 2019;112: 108700.
doi: 10.1016/j.biopha.2019.108700
Han Y, Liu D, Li L. PD-1/PD-L1 pathway: current researches in cancer. Am J Cancer Res. 2020;10(3):727–42.
pubmed: 32266087
pmcid: 7136921
Ai L, Xu A, Xu J. Roles of PD-1/PD-L1 pathway: signaling, cancer, and beyond. Adv Exp Med Biol. 2020;1248:33–59.
doi: 10.1007/978-981-15-3266-5_3
Peng DH, Rodriguez BL, Diao L, Chen L, Wang J, Byers LA, Wei Y, Chapman HA, Yamauchi M, Behrens C, et al. Collagen promotes anti-PD-1/PD-L1 resistance in cancer through LAIR1-dependent CD8(+) T cell exhaustion. Nat Commun. 2020;11(1):4520.
doi: 10.1038/s41467-020-18298-8
Menzies AM, Johnson DB, Ramanujam S, Atkinson VG, Wong ANM, Park JJ, McQuade JL, Shoushtari AN, Tsai KK, Eroglu Z, et al. Anti-PD-1 therapy in patients with advanced melanoma and preexisting autoimmune disorders or major toxicity with ipilimumab. Ann Oncol. 2017;28(2):368–76.
doi: 10.1093/annonc/mdw443
Cha JH, Chan LC, Li CW, Hsu JL, Hung MC. Mechanisms controlling PD-L1 expression in cancer. Mol Cell. 2019;76(3):359–70.
doi: 10.1016/j.molcel.2019.09.030
Eguren-Santamaria I, Sanmamed MF, Goldberg SB, Kluger HM, Idoate MA, Lu BY, Corral J, Schalper KA, Herbst RS, Gil-Bazo I. PD-1/PD-L1 blockers in NSCLC brain metastases: challenging paradigms and clinical practice. Clin Cancer Res. 2020;26(16):4186–97.
doi: 10.1158/1078-0432.CCR-20-0798
Chamoto K, Al-Habsi M, Honjo T. Role of PD-1 in immunity and diseases. Curr Top Microbiol Immunol. 2017;410:75–97.
pubmed: 28929192
Zhao N, Dang H, Ma L, Martin SP, Forgues M, Ylaya K, Hewitt SM, Wang XW. Intratumoral gammadelta T-cell infiltrates, chemokine (C–C Motif) ligand 4/Chemokine (C–C Motif) ligand 5 protein expression and survival in patients with hepatocellular carcinoma. Hepatology. 2021;73(3):1045–60.
doi: 10.1002/hep.31412